AGIO STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Encourages Long-Term Investors to Contact the Firm
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) (“Agios”) on behalf of the company’s long-term investors.
Click here for additional information: https://kaskelalaw.com/case/agios-pharma/
Since December 2024, shares of Agios’ common stock have declined in value from a trading price of over $60.00 per share to a current trading price of under $35.00 per share, a decline of over 40% in value.
The investigation seeks to determine whether Agios and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to investors in connection with recent corporate actions.
Agios shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 – 0750, or by clicking on the following link (or by copying and pasting the link into your browser):
https://kaskelalaw.com/case/agios-pharma/
Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com
This notice may constitute attorney advertising in certain jurisdictions.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
